Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, et al. Sosman JA, et al. Among authors: boldt dh. J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496. J Clin Oncol. 1993. PMID: 8336188 Clinical Trial.
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Gaynor ER, et al. Among authors: boldt dh. J Natl Cancer Inst. 1990 Sep 5;82(17):1397-402. doi: 10.1093/jnci/82.17.1397. J Natl Cancer Inst. 1990. PMID: 2388289
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Sparano JA, et al. Among authors: boldt dh. J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):216-23. doi: 10.1097/00002371-199410000-00006. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7834121 Clinical Trial.
Phase I clinical trial of carbetimer.
Hanauske AR, Melink TJ, Harman GS, Clark GM, Craig JB, Koeller JM, Boldt DH, Kantor B, Kisner DL, Orczyk G, et al. Hanauske AR, et al. Among authors: boldt dh. Cancer Res. 1988 Sep 15;48(18):5353-7. Cancer Res. 1988. PMID: 2842047
78 results